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Edited by Michael R. BubbAbstract Muscle ﬁbers attach to laminin in the basal lamina
using two mechanisms, i.e., dystrophin with its associated pro-
teins and a7b1 integrin. In humans, gene-mutation defects in
one member of these complexes result in muscular dystrophies.
This study revealed changes after L-arginine treatment of utro-
phin-associated proteins and the a7B integrin subunit in mdx
mouse, a dystrophin-deﬁcient animal model. In the two studied
muscles (cardiac muscle and diaphragm), the a7B integrin sub-
unit was increased in 5-week-old treated mice. Interestingly,
the diaphragm histopathological appearance was signiﬁcantly
improved by L-arginine administration. These results highlight
a possible way to compensate for dystrophin deﬁciency via
a7b1 integrin.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The actin network located under the muscle membrane is
linked to the extracellular laminin by two distinct mechanisms.
The ﬁrst one involves dystrophin at the inner cytoplasmic
membrane. The linkage is mediated through dystrophin asso-
ciations with transmembrane proteins, i.e., dystroglycan and
sarcoglycan–sarcospan complexes [1–3]. There are also impor-
tant associations with the subsarcolemmal complex, i.e., dys-
trobrevins, syntrophins and neuronal-type nitric oxide
synthase (nNOS) [4]. The second mechanism involves mus-
cle-speciﬁc a7b1 integrin. This transmembrane laminin recep-
tor also links the extracellular matrix with the cell
cytoskeleton of skeletal and cardiac muscles [5,6]. The dystro-
phin-associated protein complex (DAPC) and the a7b1 inte-
grin both participate in the molecular continuity between the
extracellular matrix and myoﬁbers, which is essential for mus-
cle membrane structural and functional integrity.
Defects in the dystrophin gene result in a lack of dystrophin,
which weakens muscle ﬁber association with the surroundingAbbreviations: NO, nitric oxide; PAGE, polyacrylamide gel electro-
phoresis; Ss, saline solution; SDS, sodium dodecyl sulfate
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dystrophies [7]. The absence of dystrophin is followed by per-
sistence of an homologous protein called utrophin [8]. Utro-
phin is present all around the muscle membrane during
foetal development and then only maintained at the neuromus-
cular junction in normal muscle [9]. In dystrophin-deﬁcient
muscles, utrophin remains associated along the muscle mem-
brane and links to diﬀerent dystrophin-associated partners
such as syntrophin and nNOS [10].
An absence of dystrophin partially disrupts membrane-
bound nNOS [11] followed by defects in microvascular
adaptation [12]. In contrast, a nNOS transgene improves the
muscular dystrophy phenotype [13]. Contraction of dystro-
phin-deﬁcient muscles therefore may not properly stimulate
suﬃcient NO production to release vasoconstriction, resulting
in local muscle ischemia [14].
The NO precursor is provided by L-arginine (L-Arg), which
is involved in the urea synthesis cycle and is the nNOS sub-
strate. If muscle ﬁbers produce suﬃcient level of nNOS, ele-
vated L-Arg concentrations could inﬂuence NO synthesis and
perhaps improve muscle membrane integrity. This prompted
us to treat a murine model of dystrophin deﬁciency, i.e., mdx
mouse [15], with L-Arg. Utrophin, diﬀerent members of the
DAPC and a7B integrin were analyzed in cardiac muscle
and diaphragm by Western blot and immunoﬂuorescent detec-
tion. Here, we describe speciﬁc protein changes and potential
associated improvements in muscle morphology induced by
L-Arg treatment in dystrophin-deﬁcient muscles.2. Materials and methods
2.1. Antibodies
Polyclonal antibodies directed against C-terminal sequences of a-
dystrobrevin (D124: GVSYVPYCRS), b-dystroglycan (LG5:
PPPYVPPP), dystrophin (H4: SRGNIPGKPMREDTM); sarcospan
(C525: CSLTASEGPQQKI); utrophin (K7: CPNVPSRPQAMC)
and a7B-integrin (K6: DWHPELGPDGHPVPATA) were obtained
by injecting the keyhole limpet hemocyanin-linked peptide as antigen
according to a previously described protocol [16]. K6 speciﬁcally rec-
ognize the a7B isoform of the a7 subunit in the a7b1 integrin complex.
Commercial antibodies directed against caveolin-3 and nNOS were
purchased from Santacruz Biotechnologies and BD Transduction Lab-
oratory, respectively.
2.2. Laboratory animals and L-arginine administration protocol
Wild-type (C57BL/10) and dystrophin-deﬁcient (mdx) mice were
purchased from Jackson Laboratories. Intraperitoneal injections
(250 ll vol.) were performed daily for 3 weeks. Control mdx andblished by Elsevier B.V. All rights reserved.
Fig. 1. Western blot detection of utrophin and a7B integrin in
Ss-treated C57BL/10, Ss-treated mdx and L-Arg-treated mdx mice
muscles. Western blots showing relative detection of (A) utrophin and
(B) the a7B integrin subunit in tissue lysates from 5- and 13-week-old
mice. The six left lanes contained samples from cardiac muscles, while
the six right lanes contained samples from diaphragms. (C) Coomassie
blue detection of MHC after SDS–PAGE of tissue lysates.
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treated mdx animals were administered with L-Arg solution (250 mg/
kg). Experiments were carried out on 5- and 13-week-old animals in
duplicate. Thirty-six mice were used: Ss-treated C57BL/10
(n = 2 · 6), Ss-treated mdx (n = 2 · 6) and L-Arg-treated mdx
(n = 2 · 6). Animals were killed on the 22nd day post-treatment. Dia-
phragm and cardiac muscles were dissected, rapidly frozen in 2-meth-
ylbutane, cooled in liquid nitrogen and stored at 80 C until use.
2.3. Preparation of tissue lysates
0.01 g from cardiac muscle or diaphragm were homogenized in
150 ll of SDS buﬀer (50 mM Tris/HCl, pH 8.0, 10% SDS, 5%
b-mercaptoethanol, 10% glycerol, 10 mM EDTA). Samples were cen-
trifuged at 13000 · g for 10 min. Each supernatant was mixed with
50 ll of SDS buﬀer containing 0.01% bromophenol blue. Each tissue
lysate was denatured for 3 min at 100 C and submitted in duplicate
to SDS–PAGE. One resulting gel was Coomassie blue stained and
the other was transferred onto nitrocellulose.
2.4. Scanning densitometric measurement standardization
Using the NIH Image software package, the relative optical density
of the myosin heavy chain (MHC) present in each tissue lysate was
estimated from the Coomassie blue stained gel. Independently, a stan-
dard SDS–PAGE, corresponding to known myosin amounts, was
stained with Coomassie blue. This was converted into a standard curve
associating each scanning densitometric measurement of the MHC
band with the corresponding amount of myosin. In reference to this
curve, the protein concentration was equilibrated in each tissue lysate.
2.5. Western blot analysis
Tissue lysates were electroblotted onto nitrocellulose (0.2 lm). Each
blot was blocked in Tris-buﬀered saline with 0.1% Tween 20 (TBST)
containing 3% bovine serum albumin (w/v). All membranes were incu-
bated with primary antibodies for 1 h at room temperature. After
labeling, the membranes were washed in TBST and then incubated
with the secondary antibody (phosphatase-conjugated goat anti-rabbit
IgG, Chemicon International, 1/5000). Antibody-bound proteins were
detected with p-nitroblue tetrazolium and 5-bromo-4-chloro-3-indoyl-
phosphate substrate, as previously reported [17].
2.6. Measurement of relative protein concentrations
Protein band intensities were assessed using the NIH Image software
package. Means of arbitrary values obtained for the two assays were
calculated. To test for statistically signiﬁcant diﬀerences, a one-way
analysis of variance (ANOVA) was used; in the case of signiﬁcant dif-
ferences, the Scheﬀe test was applied. Statistical signiﬁcance was set at
P < 0.05. Means of arbitrary values were translated into mean percent-
ages by considering the C57BL/10 mean of the arbitrary value as 100%.
Data were expressed as means ± SEM (in %).
2.7. Immunoﬂuorescence studies
Unﬁxed cryostat sections (10 ll thick) of frozen diaphragm and car-
diac muscles were incubated with anti-utrophin or anti-a7B integrin
antibody for 1 h at room temperature on slides. After washing with
phosphate-buﬀered saline (PBS), sections were incubated for 1 h at
room temperature with the secondary antibody (Cy3-conjugated goat
anti-rabbit IgG, Chemicon International, 1/4000). Finally, the sections
were washed with PBS, the slides were then mounted with Mowiol
(CalBiochem) and observed under a Nikon optiphot-2 microscope.
2.8. Histological analysis
Unﬁxed cryostat sections (10 ll thick) of frozen cardiac muscle and
diaphragm from 5-week-old mice were incubated with haematoxylin
(Sigma). After washing with distilled water, sections were incubated
with eosin (Sigma). Finally, the sections were washed, the slides were
then mounted with Mowiol and observed under a Nikon optiphot-2
microscope.
A subsequent image analysis was performed using the ImageTool
IT3 software package. Muscle ﬁber cross-sections were analyzed in
three steps: (a) determination of the muscle ﬁber size, (b) determination
of the percentage of muscle ﬁbers containing centralized nuclei and (c)
assessment of the lymphocytic invasion. The geometrical parametertested for the determination of the muscle ﬁber size was the minimal
‘‘Ferets diameter’’ (the minimum distance of parallel tangents at
opposing borders of the muscle ﬁber) according to recent published
data [18]. The variance coeﬃcient (VC) of the ‘‘Ferets diameter’’ is de-
ﬁned as follows: VC = (standard deviation of the ‘‘Ferets diameter’’/
mean muscle ﬁber size) · 1000. The lymphocytic invasion was evalu-
ated by measuring the inﬂammatory area as a percentage of the total
area muscle cross-section.3. Results
3.1. L-Arg treatment does not signiﬁcantly alter the utrophin
level in mdx mouse cardiac muscle and diaphragm
We ﬁrst attempted to determine whether L-Arg treatment
would modify protein levels in muscles. Tissue lysates from
cardiac muscle and diaphragm were subjected to Western blot
analysis with antibodies directed against utrophin, a7B-inte-
grin and dystrophin-associated proteins (i.e., caveolin-3, a-dys-
trobrevin, b-dystroglycan, nNOS and sarcospan).
As expected, saline solution (L-Arg-diluent) did not modify
the protein levels in Ss-treated C57BL/10 and Ss-treated mdx
mice, as compared with protein levels in untreated mice (data
not shown). In addition, L-Arg treatment had no signiﬁcant ef-
fect on caveolin-3, a-dystrobrevin, b-dystroglycan, nNOS and
sarcospan levels in both 5- and 13-week-old mdx mice (data
not shown).
Fig. 1A shows the utrophin band obtained with the K7
polyclonal antibody and Fig. 2A shows the relative utrophin
concentrations (percentage) in each treated animal-type. In
each studied muscle, we observed clear overexpression of
utrophin in Ss-treated mdx mice relative to Ss-treated
C57BL/10 mice as previously showed [19]. Histograms re-
vealed that L-Arg treatment had no eﬀect on cardiac utrophin
level in 5-week-old mdx mice. Surprisingly, L-Arg treatment
reduced the cardiac utrophin level in 13-week-old mdx mice.
Finally, diaphragm utrophin levels appeared increased in
5- and 13-week-old L-Arg-treated mdx mice but it was not
signiﬁcant according to our statistical tests (Fig. 2A).
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Fig. 2. Histogram analysis after utrophin and a7B integrin detection
in Ss-treated C57BL/10, Ss-treated mdx and L-Arg-treated mdx mouse
muscles. Histograms showing relative concentrations of (A) utrophin
and (B) the a7B integrin subunit in tissue lysates from 5- and 13-week-
old mice. The symbol * indicates that concentrations of protein
diﬀered signiﬁcantly at P < 0.05.
Fig. 3. Immunohistochemistry of the utrophin and a7B integrin
distribution in 5-week-old mouse muscles. Cryostat sections of (A)
cardiac muscle and (B) diaphragm from Ss-treated C57BL/10, Ss-
treated mdx and L-Arg-treated mdx mice were analyzed. Ss-treated
C57BL/10, Ss-treated and L-Arg-treated mdx mice were studied
comparatively using polyclonal antibodies against utrophin and the
a7B integrin subunit. In the insert, a revertant ﬁber in Ss-treated mdx
diaphragm revealed by H4 antibody.
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mouse cardiac muscle and diaphragm
Interestingly, a7B integrin levels were signiﬁcantly increased
after L-Arg treatment in cardiac muscle and diaphragm from
5-week-old mdx mice compared to 5-week-old Ss-treated
mdx mice (Figs. 1B and 2B).
To independently conﬁrm these observations, frozen cardiac
muscle and diaphragm tissue sections from 5-week-old mdx
mice were prepared and examined by immunoﬂuorescence.
Fig. 3A shows utrophin and a7B integrin staining of cardiac
cross-sections. Utrophin immunostaining of the Ss-treated
C57BL/10 cardiac muscle essentially revealed microvessels
(Fig. 3A, panel 1). In contrast, utrophin was present all along
the sarcolemma in Ss-treated mdx mice, as expected. Finally,
utrophin immunostaining was quite similar in Ss-treated and
in L-Arg-treated mdx cardiac muscle. In cardiac muscles,
a7B integrin immunoﬂuorescence did not markedly increase
in stained plasma membrane when comparing Ss-treated
mdx and L-Arg-treated mdx muscles (Fig. 3A, panel 2).
Fig. 3B shows utrophin and a7B integrin staining of dia-
phragm cross-sections. Utrophin immunostaining of the Ss-
treated C57BL/10 diaphragm essentially revealed microvessels,
as observed in cardiac muscle. In contrast, utrophin was pres-
ent along the sarcolemma, and was quite similar in Ss-treated
and L-Arg-treated mdx diaphragms (Fig. 3B, panel 3). a7B
integrin immunostaining of Ss-treated C57BL/10 diaphragm
revealed all the ﬁber membrane, as expected (Fig. 3B, panel4). In Ss-treated mdx diaphragm, a7B integrin immunostaining
of the ﬁber membrane was less marked than in Ss-treated
C57BL/10. In addition, one revertant ﬁber showed intensive
a7B integrin immunostaining (indicated with an arrow and
in insert). As expected, in diaphragm, the amount of ﬂuores-
cence detected in L-Arg-treated mdx diaphragm exceeded that
of the Ss-treated mdx sample. In addition, in L-Arg-treated
mdx diaphragm, immunoﬂuorescence staining of a7B integrin
was increased in comparison to what we observed in Ss-treated
C57BL/10 mice (Fig. 3B, panel 4).
3.3. L-Arg treatment improves muscle morphology in mdx
diaphragm
We ﬁnally attempted to evaluate whether L-Arg treatment,
would improve the overall muscle pathology of these muscles.
Thus, we performed H&E staining of frozen cardiac muscle
and diaphragm sections from 5-week-old mdx mice.
Cardiac muscle sections from Ss-treated and L-Arg-treated
mdx mice were relatively similar to cardiac muscle sections
from Ss-treated C57BL/10 mice (Fig. 4A). One possible expla-
nation could be that cardiac muscle showed no regenerative
capacity compared to skeletal muscle.
In contrast, diaphragm sections from Ss-treated mdx mice
showed clear signs of dystrophic changes, including muscle ﬁ-
ber size variations (VC = 393.7 ± 15.1), central nuclei
(21.5 ± 0.9), lymphocytic invasion (16.0 ± 1.4) (Fig. 4B and
C). Interestingly, an analysis of diaphragm muscle sections
Fig. 4. Histology of 5-week-old mouse muscles. Cryostat sections of (A) cardiac muscle and (B) diaphragm from Ss-treated C57BL/10, Ss-treated
mdx and L-Arg-treated mdx mice were subjected to H&E staining and to (C) quantitative analysis by histomorphometry. (a) Variance coeﬃcient of
the minimal ‘‘Ferets diameter’’, (b) percentage of muscle ﬁbers with centralized nuclei and (c) percentage of lymphocytic invasion of multiple mouse
cross-sections were compared in diaphragm. To test for statistically signiﬁcant diﬀerences, an ANOVA was used; in the case of signiﬁcant diﬀerences,
the Scheﬀe test was applied. The symbol *** indicates that data diﬀered signiﬁcantly at P < 0.0001. The summary values are reported in the table.
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nucleated muscle ﬁbers (14.0 ± 1.3), more uniform ﬁber diam-
eters (247.0 ± 9.9), and low signs of lymphocytic invasion
(6.4 ± 0.8), thus suggesting that the dystrophic process was re-
duced (Fig. 4B and C).4. Discussion
Our results revealed that 3 weeks of intraperitoneal injec-
tions of L-Arg had no signiﬁcant eﬀect on utrophin level in5-week-old mdx cardiac muscle. On the contrary, utrophin
was downregulated in L-Arg-treated mdx 13-week-old cardiac
muscle (compared to Ss-treated mdx cardiac muscle). Finally,
utrophin showed an increase in 5- and 13-week-old L-Arg-trea-
ted mdx diaphragm (compared to Ss-treated mdx diaphragm)
but the standard error was too high to conclude to a signiﬁcant
positive eﬀect. These observations in cardiac muscle and dia-
phragm supplement but do not conﬁrm previous results [20],
which reported that L-Arg treatment of three adult mdx mice
increased utrophin levels in skeletal muscles diﬀerent than
diaphragm, i.e., biceps femoris and semitendinosus muscles.
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by (i) the L-Arg dose applied (250 mg/kg/day in our experi-
ments vs 200 mg/kg/day in previous experiments), (ii) the
age-related physiopathology of the mdx muscle when L-Arg
treatment is begun (5- and 13-week-old animals vs unspeci-
ﬁed-aged animals) and (iii) the diﬀerent muscle types studied
(cardiac muscle and diaphragm vs biceps femoris and semiten-
dinosus muscles). Further experiments will be necessary to
clarify theses points. Note, however, that the mdx mouse
strain, which lacks dystrophin in all of its muscles, exhibits
high between-muscle variability in myoﬁber necrosis and con-
tractile properties. Their hindlimb muscles undergo extensive
myoﬁber degeneration and regeneration from 3 to 5 weeks of
age [21], which continues on a more limited scale for the dura-
tion of their life cycle. Although hindlimb muscles of mdx mice
undergo successful regeneration, mdx mouse diaphragm exhib-
its muscle pathology very similar to DMD. The underlying
mechanisms by which dystrophin deﬁciency mediates the ob-
served pathophysiological changes in mdx mice are unclear.
However, a recent paper indicates that distinct signaling path-
ways are diﬀerentially activated in diaphragm and tibialis ante-
rior muscle of dystrophic mice [22]. The results notably
demonstrate that p38 activity is decreased in diaphragm, the
muscle that displays the more severe phenotype in mdx mouse
strain. This stress activated protein kinase p38 is the down-
stream target of multiple growth factors, NO and integrin-
mediated signaling [23].
Our analysis of cardiac muscle and diaphragm from L-Arg
mdx treated mice also showed that 3 week intraperitoneal
injections of L-Arg had a signiﬁcant eﬀect on the a7B integrin
level in 5-week-old mdx muscles. The exact reasons for this are
unclear but may be related to the a7B integrin localisation and
function in muscle ﬁbers. In skeletal and cardiac muscle mem-
branes, the DAPC is concentrated in costameres [24]. The ma-
jor integrin complex of cardiac and skeletal muscle (a7b1) is
also concentrated in costameres [25]. Costameres are thought
to transmit mechanical force from sarcomeres to the sarco-
lemma, the extracellular matrix and even surrounding ﬁbers
and require both outside-in and inside-out signaling [26].
Direct interaction between integrins and the DAPC has not
been shown, but immunoprecipitation studies suggest bidirec-
tional signaling between these complexes. In cultured L6 myo-
cytes, the anti-b1 integrin subunit co-precipited components of
the DAPC [27]. In addition, a7-integrin and dystrophin repre-
sent associated adhesion protein complexes during muscle
regeneration [28].
Finally, in our study, no increase in nNOS level was ob-
served after stimulation of the nNOS pathway by L-Arg injec-
tion (data not shown), even if, contrary to DMD, the mdx
mouse strain exhibits a low but detectable nNOS level and
activity [11]. However, the a7B integrin level increase that we
observed after L-Arg treatment in 5-week-old mdx mice was
accompanied by a signiﬁcant improvement in the histopathol-
ogical appearance in the diaphragm. This improvement could
be related to intracellular Ca2+ levels which are in part regu-
lated by signaling through the a7b1 integrin [29]. This integrin
may contribute to the maintenance of calcium levels in myof-
ibers. In dystrophic muscle, the intracellular Ca2+ increase may
activate Ca2+-dependent proteolysis and increase muscle
degeneration [30]. If so, the a7B integrin level increase that
we observed after L-Arg treatment in 5-week-old mdx mice
may regulate the activity of calcium channels, stabilizingintracellular Ca2+ levels in mdx ﬁbers and reducing muscle
degeneration.
The increased a7B integrin level was not observed after
L-Arg treatment in 13-week-old mdx muscles. This could be
attributed to the age-related physiopathology of the mdx mus-
cle when L-Arg treatment is begun (5-week-old animals vs
13-week-old animals). Then, based on histomorphometric
assessment, the increased a7B integrin-associated-improve-
ment in the histopathological appearance was particularly evi-
dent in 5-week-old mdx diaphragms as stated in Fig. 4. This
indicates that only within the short period at around 5-week-
old when a large number of muscle ﬁbers undergoes degener-
ation, drug candidates like L-Arg may have a therapeutic eﬀect
on dystrophic process.Acknowledgments: We thank Mrs. Chantal Jacquet for her technical
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